Skip to content
MarketScale
‹ Back to IndustriesEngineering & Construction

What Are the Biggest Challenges Pharmaceutical Manufacturers Are Facing Today?

Pharmaceutical manufacturers face significant challenges such as ensuring quality control, navigating regulatory requirements, and managing supply chain disruptions. These issues are intensified by the need for innovation and rapid response to market demands. Companies must balance these factors to remain competitive in the industry.

This story was produced through MarketScale. See how Engineering & Construction teams put it to work with Partner & Channel Enablement.

Promoted content from Syntegon on MarketScale.

By JORDAN CARDER ·
Share

Key takeaways

01

Quality control is a major challenge for pharmaceutical manufacturers.

02

Regulatory compliance is essential but can be complex and time-consuming.

03

Supply chain disruptions require strategic management and contingency planning.

Pharmaceutical manufacturers are under persistent pressure to deliver product on time, at scale, and without disruption. As demand patterns shift and supply chains remain unpredictable, the operational gaps that once seemed manageable have become critical bottlenecks. One challenge in particular keeps surfacing across the industry: the gap between incoming orders and available production capacity.

Ready-to-go capacity is the central pain point

The problem is straightforward, but the implications are significant. Manufacturers are securing orders, yet they lack the equipment on the floor to fulfill them when it matters. As one industry voice put it directly: "The top challenges my customers are facing right now is ready-to-go capacity. So oftentimes, they're getting orders, but they don't have the machines that are available at that time to run that product."

This mismatch between order intake and machine availability creates a compounding problem. Delivery timelines slip, customer relationships strain, and manufacturers are forced into reactive decisions, whether that means rushing equipment procurement, outsourcing production, or pushing back on commitments they have already made. None of those options are ideal, and all of them carry cost.

The issue is not simply about having too few machines in general. It is about having the right machines, qualified and ready to run a specific product, at the specific moment an order arrives. In a regulated industry like pharmaceuticals, equipment cannot be swapped in overnight. Validation, compliance requirements, and change control processes all add lead time between acquiring a piece of equipment and actually running product on it.

Planning and flexibility as a competitive advantage

Manufacturers that find ways to maintain flexible, pre-qualified capacity, whether through scalable equipment strategies, contract manufacturing partnerships, or more dynamic capacity planning, are better positioned to convert orders into shipped product without delays. The ability to respond quickly to demand is increasingly a differentiator, not just an operational goal.

Addressing the ready-to-go capacity gap requires a longer planning horizon and closer alignment between commercial teams and operations. When sales commitments are made without a clear line of sight into equipment availability, the production floor absorbs the consequences. Closing that communication loop, and building capacity buffers into long-range plans, is where manufacturers can make real gains against this persistent challenge.

Syntegon

Part of this channel

Syntegon

News, updates, and expert insights from Syntegon.

Visit the channel

About the author

JC
JORDAN CARDER

Engineering & Construction: are you visible to AI?

Before they reach out, Engineering & Construction buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Engineering & Construction expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Engineering & Construction expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Engineering & Construction Insights

What Challenges Are Manufacturers Facing Under Annex 1?

What Challenges Are Manufacturers Facing Under Annex 1?

Manufacturers are facing significant challenges under Annex 1, which regulates sterile production processes. Compliance with these regulations is critical for maintaining product safety and quality. Identifying potential risks and implementing effective control measures are key aspects for manufacturers to address.

  • 01Annex 1 presents challenges in maintaining sterile production processes for manufacturers.
  • 02Compliance with Annex 1 regulations is crucial for product safety and quality.
  • 03Manufacturers must identify risks and implement effective control measures.

Aug 3, 2026

U.S. warehouse construction jumps 18% as data-center supply chains drive industrial real estate recovery

U.S. warehouse construction jumps 18% as data-center supply chains drive industrial real estate recovery

Industrial real estate construction in the U.S. reached over 305 million square feet in the second quarter of 2026, an 18% increase from the previous year. The surge is largely driven by demand from data-center equipment suppliers. This trend highlights the growing influence of data centers on industrial real estate recovery.

  • 01U.S. industrial real estate construction increased by 18% year-over-year in Q2 2026.
  • 02Demand for new constructions is primarily driven by data-center equipment suppliers.
  • 03Over 305 million square feet of industrial space is under development.

Aug 1, 2026

U.S. industrial vacancy falls below 7% as Q2 2026 leasing hits its strongest pace since mid-2022

U.S. industrial vacancy falls below 7% as Q2 2026 leasing hits its strongest pace since mid-2022

Cushman & Wakefield's Q2 2026 report reveals a net absorption of 62.1 million square feet in the U.S. industrial market, with vacancy rates falling below 7%. This trend is significantly impacting lease negotiation leverage for industrial occupants.

  • 01Net absorption in the U.S. industrial market reached 62.1 million square feet in Q2 2026.
  • 02Vacancy rates in the U.S. industrial sector have tightened to below 7%.
  • 03Strong leasing activity is reshaping negotiation leverage for industrial tenants.

Aug 1, 2026

Explore More Engineering & Construction Insights

Read more expert perspectives from across Engineering & Construction.

Browse Engineering & Construction Hub

About the Expert

JC
JORDAN CARDER

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Engineering & Construction and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512